Meds & supplements › Alglucosidase alfa
Medicine · Hydrolytic Lysosomal Glycogen-specific Enzyme
Alglucosidase alfa
LUMIZYME ® is a hydrolytic lysosomal glycogen-specific enzyme indicated for patients with Pompe disease (acid α-glucosidase [GAA] deficiency).
Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗
Drug facts
- Used for
- LUMIZYME ® is a hydrolytic lysosomal glycogen-specific enzyme indicated for patients with Pompe disease (acid α-glucosidase [GAA] deficiency).
Side effects, and when to stop
The following serious adverse reactions are described below and elsewhere in the labeling:
- Hypersensitivity Reactions Including Anaphylaxis
Who should not take it
None.
Storing it
Store LUMIZYME under refrigeration between 2°C and 8°C (36°F and 46°F). Do not use LUMIZYME after the expiration date on the vial.
Cite this page
- NLM
sofidex [Internet]. Daloreum; c2026. Alglucosidase alfa; [reviewed 2026 Aug 2; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/alglucosidase-alfa
- APA 7th
sofidex. (2026, August 2). Alglucosidase alfa. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/alglucosidase-alfa
- AMA 11th
Alglucosidase alfa. sofidex. Reviewed August 2, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/alglucosidase-alfa
The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.